Where the Five-to-Seven Days Actually Go
GDP-compliant disposition requires three things to happen in sequence: retrieving temperature excursion data from Sensitech TempTale loggers, reconciling the chain of custody in SAP, and getting a pharmacist to review and approve the disposition. None of these steps is technically complex — but each requires a different system, a different person, and often a different shift. The compounding wait means a return that arrives Monday may not clear until the following week. For temperature-sensitive products with narrow remaining shelf life, that window is the difference between resale value and a write-off.
Compressing Disposition to a Four-Hour Window
An AI Labor Company agent built for this workflow reads Sensitech TempTale logger data for the return shipment automatically on receipt, pulls the complete chain of custody from SAP S/4HANA, and evaluates temperature excursion against the product's stability limits — the same comparison a quality analyst would make, completed in minutes rather than days. The output is a GDP-formatted disposition assessment recommendation in Veeva Vault QMS, with all supporting documentation attached and properly formatted for pharmacist review. The pharmacist approves or modifies the recommendation directly in Veeva — a decision that now takes under 4 hours from return receipt, not 5 to 7 days. Teams chat in Microsoft Teams keeps the relevant stakeholders notified at each stage without manual status updates.
Revenue Recovery, Not Just Efficiency
The business case here is primarily about recovering product revenue that is currently being written off due to disposition delay. When recoverable returns expire in quarantine, the lost product value accumulates quietly — it doesn't appear as a discrete penalty, but it compounds across volume. Faster disposition means more product cleared for resale before its shelf-life window closes. The efficiency gain — 60–80% reduction in disposition cycle time — is the mechanism; the revenue recovery from reduced write-offs is the outcome. An agent of this type is typically live in about 5 weeks.
Does the pharmacist still make the final disposition call, or does the agent decide?
The pharmacist retains full decision authority. The agent prepares the assessment and documentation; the pharmacist reviews and approves in Veeva Vault. Nothing is automatically dispositioned — the GDP requirement for qualified person sign-off is preserved.
What happens if the temperature excursion data indicates the product is clearly non-conforming?
The agent generates the appropriate GDP deviation record and disposition recommendation — which in that case would flag for destruction or return to manufacturer — and routes it to the pharmacist the same way. The workflow handles both 'approved for resale' and 'reject' outcomes; the pharmacist makes the call on the evidence the agent assembles.